Drugs / IL-6R Monoclonal Antibody
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05232396 | Mar → Oct 2021 | rheumatoid arthritis | Beijing VDJBio Co., LTD. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-6R Monoclonal Antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05232396 ↗ |
| Modality | Monoclonal antibody | “Recombinant Humanized IL-6R Monoclonal Antibody Injection” NCT05232396 ↗ |
| Route | Intravenous | “each patient receives a single intravenous(i.v.) dose.” NCT05232396 ↗ |